Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is well-positioned in the structural heart disease market with a diverse portfolio of products, a strong global presence, and a solid track record of growth. The company's financial performance and latest guidance, including expectations for increased revenue and EPS, reflect its continued strength in the market. With multiple catalysts on the horizon, including potential expansions into new indications and product launches, Edwards Lifesciences has potential for further growth and market leadership.

Bears say

Edwards Lifesciences is a global leader in the rapidly growing TAVR market, with a significant share in both the U.S. and global markets. However, the company's recent proposal to remove the CMS Coverage with Evidence Development (CED) requirement for TAVR procedures may not have as significant of an impact on procedure volume as initially anticipated. Moreover, while EW's innovative TAVR device, SAPIEN X4, is highly anticipated, there is potential for increased competition from new entrants or newer innovations from existing competitors. Additionally, the company's lack of diversification in its product portfolio, with a heavy reliance on TAVR for revenue, could pose a risk in the future.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.